Slides last updated: March 2015. There are two main types of lung cancer 1 1.Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review,

Slides:

Advertisements

Similar presentations

Cedars Sinai Medical Center

Advertisements

Treatment in Advanced Non-Small Cell Lung Cancer.

EGFR Mutation Testing From the Pathologist’s Point of View

ENT Gerard Kelly and general practice The Leeds Teaching

Vinni Swad Zander Thompson

By Russell Armstrong Supervisor Mrs Wei Ji Diagnosis Analysis of Lung Cancer by Genome Expression Profiles.

Computed Tomography Contrast-enhanced helical CT of the thorax and abdomen that includes the liver and adrenal glands is the standard radiologic investigation.

Tobacco Cessation: Curb the Deadliest Epidemic Keith Bradley, MD Director, Research Associates Program at St. Vincent’s National Alliance of Research Associates.

90% survival rate Stage 1 68% Survival rate Stage 2 59% survival rate Stage 3 5% If spread to brain Stage 4 Ages 0 to 19 is 0.7% Ages 20 to 34 is 7.1%

Pulmonary Neoplasia Prof. Frank Carey. Lung Neoplasms r Primary l benign (rare) l malignant (very common) r Metastatic (Very common)

Prevention Strategies: Emerging Trends and Issues Kimberly E. Davis, Ph.D. July 17, 2010 Center for Cancer Research and Therapeutic Development.

Overview of All SEER-Medicare Publications Through 2012 Mark D. Danese, MHS, PhD July 24, 2012.

Thorax / Lung Basic Science Conference 12/21/2005 J.R. Nitzkorski.

Virus and Cancer.

Chapter 28 Lung Cancer. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Objectives  Describe the epidemiology of.

Slides last updated: June 2015 CRC: CLINICAL FEATURES.

Slides last updated: October Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality.

Slides last updated: October There are two main types of lung cancer 1 1.Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review,

LUNG ADENOCARCINOMAS. CLINICOPATHOLOGICAL STUDY WITH RESPECT TO THE UPCOMING NEW CLASSIFICATION AND EGFR-KRAS MUTATION ANALYSIS IMPLICATIONS. First author:

Unknown Primary Tumors: Newer Concepts and Approches “ 10 years experience of a Comprehensive Cancer Center” Valerio Ramazzotti S.C. Epidemiologia Roma.

10/16/2015C.R. Apap1 Lung cancer: a preventable disease Epidemiology addresses issues related to   Heredity,  Life-style, and  Environment.

Bronchogenic Carcinoma. most commonly diagnosed cancer worldwide most common cause of cancer death in both men and women Lung cancer kills more people.

Slides last updated: October Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality.

Differentials. INFLAMMATORY Pulmonary Tuberculosis History of cough Chest X-ray findings (+) PPD test.

Malignant tumor of the respiratory system Nasopharygeal carcinoma Lung cancer.

Slides last updated: March 2015 CRC: EPIDEMIOLOGY.

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.

2015/ NON-SMALL CELL LUNG CANCER (NSCLC) 1.1 Adenocarcinomas are often found in an outer area of the lung. 1.2 Squamous cell carcinomas are usually.

Overall survival in NSCLC

NMDT (%)Path (%)NOS (%)CNS (%) Weston Area Health  70.5  5.7  66.3  Yeovil District Hospital  54.9  22.9  82.9  University Hospitals.

Slides last updated: March Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN.

40-year War on Cancer not going too well ● Age-adjusted death rate today not much different from rate in the mid-20 th century (rate rises from.

Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.

Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,

CLINICAL ASPECT OF GRADING AND STAGING Hanggoro Tri Rinonce, MD, PhD Department of Anatomical Pathology Faculty of Medicine, Gadjah Mada University.

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD

More Ontarians need to be screened for colorectal cancer (Sept. 2012)

Algorithm for adenocarcinoma diagnosis in small biopsies and/or cytology. Step 1: When positive biopsies (fiberoptic bronchoscopy [FOB], transbronchial.

Approach to the Ground-Glass Nodule

Advanced stage non–small cell lung cancer treatment algorithm

Stereotactic ablative radiotherapy (SABR) versus lobectomy for operable stage I NSCLC Julia Myers.

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Figure 4 Example of a patients with CUP

Lung Cancer Screening. The Pulmonologist’s Role in Improving Personalized Diagnosis and Treatment of NSCLC.

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Figure 2 Differences between MC and AC

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Genomic Testing: When and Why

A Histologic Basis for the Efficacy of SBRT to the lung

CT Characteristics and Pathologic Basis of Solitary Cystic Lung Cancer

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome Luisella Righi, MD, PhD, Tiziana Vavalà, MD, Ida.

CUP is a clinico-pathological syndrome of many specific cancer

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Trends in survival from metastatic lung cancer in California,

CHCHD2 and EGFR protein expression in NSCLC

NSCLC: Staging and TNM classification

Prevalence of germline T790M.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Comparison of primary end-points against guidelines

Gastric, lung, and HPV-related cancer incidence and model fits.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

ENTPD5 expression correlates with EGFR and activated AKT levels in human NSCLC. A, percentages of PTEN-low lung adenocarcinoma cases with at least one.

Examples illustrating the study definitions of groups A, B, and C

Presentation transcript:

Slides last updated: March 2015

There are two main types of lung cancer 1 1.Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, , National Cancer Institute. Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site, April 2014, accessed on 12/03/ % 83.6%

NSCLC (83.6% of lung cancer) Lung Cancer (100%) Other NSCLC (19.1% of lung cancer) Squamous cell carcinoma (18.6% of lung cancer) Adenocarcinoma (44.1% of lung cancer) NSCLC can be further divided into different sub-types 1 1.Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, , National Cancer Institute. Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site, April 2014, accessed on 12/03/2015.

NSCLC: Adenocarcinoma Adenocarcinoma Adenocarcinoma lesions are usually peripherally located 2 Most frequent in women and non-smokers 2 Some patients have EGFR/ErbB1 mutations; these patients require a specific diagnosis and treatment approach 3 1.Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, , National Cancer Institute. Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site, April 2014, accessed on 12/03/ Lortet-Tieulent J, Soerjomataram I, Ferlay J, et al. Lung Cancer 2014;84:13– National Comprehensive Cancer Network. NCCN guidelines version for non-small cell lung cancer. Available online at: [accessed 12/03/2015]. 44.1% 1

18.6% 1 NSCLC: Squamous cell carcinoma Squamous Cell Carcinoma 2 Squamous Cell Carcinoma lesions are generally centrally located, near bronchi Tends to spread locally Closely correlated with smoking 1.Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, , National Cancer Institute. Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site, April 2014, accessed on 12/03/ Heighway J & Betticher DC. Atlas Genet Cytogenet Oncol Haematol. February % 1

2.0% 1 NSCLC: Large cell carcinoma Large Cell Carcinoma Comprised of undifferentiated cells 2 Lesions are usually peripherally located but can occur anywhere 2 High tendency to metastasize 2 1. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, , National Cancer Institute. Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site, April 2014, accessed on 12/03/ Heighway J & Betticher DC. Atlas Genet Cytogenet Oncol Haematol. February % 1

19.1% 1 NSCLC: Other Other, including Not Otherwise Specified (NOS) or Unknown A classification of NOS or unknown is usually due to ineffective sampling and examination 2 This classification is expected to decline in use due to more accurate biopsies and advances in immunohistochemistry and biomarker testing 2 1. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, , National Cancer Institute. Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site, April 2014, accessed on 12/03/ Righi L, Graziano P, Fornari A, et al. Cancer 2011;117:3416 ‒ 3423.